title: Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands.
abstract: BACKGROUND
  The clinical behavior and treatment outcomes of salivary gland myoepithelial carcinoma have yet to be clearly defined. The current study investigated risk factors and prognoses for this tumor.
  
  
  METHODS
  A retrospective review of the medical records for 32 patients with myoepithelial carcinoma of the major salivary glands was performed. Their clinical parameters were assessed to identify correlations with local-regional recurrence, distant metastasis, and survival.
  
  
  RESULTS
  The 5-year survival rate was 71 %. Of the reviewed patients, 41 % had local-regional recurrences, and 22 % had distant metastases. Age of 60 years or younger was a predictive factor for distant metastasis. Patients with neck lymph nodes clinically positive for carcinoma had shorter overall survival durations than those with nodes negative for carcinoma.
  
  
  CONCLUSIONS
  Myoepithelial carcinoma of the major salivary glands is characterized by a high incidence of local-regional recurrence and distant metastasis. Adjuvant therapy is indicated for selected patients with high-risk disease.
authors: Discipline of Oral & Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, Hong Kong, People's Republic of China.|Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Yu-Xiong
authors: YX
authors: Su
authors: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Dianna B
authors: DB
authors: Roberts
authors: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Ehab Y
authors: EY
authors: Hanna
authors: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Adel
authors: A
authors: El-Naggar
authors: Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
authors: Güleser
authors: G
authors: Saylam
authors: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Steven J
authors: SJ
authors: Frank
authors: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Randal S
authors: RS
authors: Weber
authors: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mekupfer@mdanderson.org.
authors: Michael E
authors: ME
authors: Kupferman
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009208:Myoepithelioma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D009333:Neck; D037981:Neck Dissection; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010307:Parotid Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012307:Risk Factors; D013365:Submandibular Gland Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents